The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

Express News | Summary of shareholdings reductions by listed companies on November 26.

BreakingsNov 26, 2024 22:06

GenScript Biotech Corporation (301509.SZ): Qilu Investment, Blue Zone Fund, and Qingsong Investment plan to collectively reduce their shareholding by no more than 9%.

On November 26th, Gelonhui reported that Jinkai Life Science (301509.SZ) announced its plan to reduce its shares by no more than 3,612,000 shares (3% of the total share capital) through block trading and bulk trading. Blue Zone Fund also plans to reduce its shares by no more than 3,612,000 shares (3% of the total share capital) through block trading and bulk trading. Qingsong Investment also plans to reduce its shares by no more than 3,612,000 shares (3% of the total share capital) through block trading and bulk trading.

Gelonghui FinanceNov 26, 2024 19:10

Express News | Jinkai Life Science: Shareholders plan to collectively reduce their shareholding by no more than 9% of the company's shares.

BreakingsNov 26, 2024 18:47

Jinkai Shengke: Report for the third quarter of 2024

SZSIOct 24, 2024 00:00 · Announcements

Genecast Biotechnology (301509.SZ): The company's products do not involve starch or other fillers and excipients.

Golden Triumph October 23rd | Jin Kaiseng Science (301509.SZ) stated on the investor interaction platform that the company provides small molecule CDMO services, and the company's products do not involve starch and other fillers and excipients.

Gelonghui FinanceOct 23, 2024 17:12